BREAKING ADVANCES

2927 | Highlights from Recent Cancer Literature

REVIEWS

2929 | AMPK: A Contextual Oncogene or Tumor Suppressor?
Jiyong Liang and Gordon B. Mills

2936 | KDM4/JMJD2 Histone Demethylases: Epigenetic Regulators in Cancer Cells
William L. Berry and Ralf Janknecht

PERSPECTIVES

2943 | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Yuhui Huang, Shom Goel, Dan G. Duda, Dai Fukumura, and Rakesh K. Jain

MEETING REPORT

2949 | Center of Cancer Systems Biology Second Annual Workshop—Tumor Metronomics: Timing and Dose Level Dynamics
Philip Hahnfeldt, Lynn Hlatky, and Giannoula Lakka Klement

CLINICAL STUDIES

2955 | Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
Amanda G. Hansen, Tanner J. Freeman, Shanna A. Arnold, Alina Starchenko, Michael A. Gilger, Mary K. Washington, Kang-Hsien Fan, Yu Shyr, Robert D. Beauchamp, and Andries Zijlstra

MICROENVIRONMENT AND IMMUNOLOGY

2987 | Vaccination for Invasive Canine Meningioma Induces In Situ Production of Antibodies Capable of Antibody-Dependent Cell-Mediated Cytotoxicity

Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing
Ellen Heitzer, Martina Auer, Christin Gasch, Martin Fichler, Peter Uhl, Eva Maria Hoffmann, Sigurd Lax, Julie Waldisquell-Geigli, Oliver Mauermann, Carolin Lackner, Gerald Höfler, Florian Eisner, Heinz Sill, Hellmut Samonigg, Klaus Pantel, Sabine Riethdorf, Thomas Bauernhofer, Jochen B. Geigl, and Michael R. Speicher

Précis: This study paves the way to use circulating tumor cells as a liquid biopsy in cancer patients, providing more effective options to monitor tumor genomes that are prone to change during progression, treatment, and relapse.

Response Classification Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression
Maxwell Lewis Neal, Andrew D. Trister, Sunyoung Ahn, Anne Baldock, Carly A. Bridge, Laura Guyman, Jordan Lange, Rita Sodt, Tyler Cloke, Albert Lai, Timothy F. Cloughesy, Maciej M. Mrugala, Jason K. Rockhill, Russell C. Rockne, and Kristin R. Swanson

Précis: Results describe a novel and simple method to measure the effectiveness of glioblastoma therapies during periods of treatment when timely adjustments may be made to improve patient outcomes.
Adipocytes Cause Leukemia Cell Resistance to L-Asparaginase via Release of Glutamine
Ehsan A. Ehsanipour, Xia Sheng, James W. Behan, Xingchao Wang, Anna Butturini, Vassilios I. Avramis, and Steven D. Mittelman

Molecular and Cellular Pathobiology
Inhibition of Histone Demethylase JMJD1A Improves Anti-Angiogenic Therapy and Reduces Tumor-Associated Macrophages
Tsuyoshi Osawa, Rika Tsuchida, Massashi Muramatsu, Tepppei Shimamura, Feng Wang, Jun-ichi Suehiro, Yasuharu Kanki, Youichiro Wada, Yuhihiyo Yuyasa, Hiroyuki Ichihara, Hiroaki Asano, Kazunori Tsukuda, Nagio Takigawa, Katsuya Kiura, Adi F. Gazdar, Wan L. Lam, and Shinichiro Miyoshi

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY
Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor– Initiating Cells
Jun Fu, Dimpy Koul, Jun Yao, Shuzhen Wang, Ying Yuan, Howard Colman, Erik P. Sulman, Frederick F. Lang, and W.C. Alfred Yung

Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
Wenxin Xu, Monica Jones, Bai Liu, Xiaoyun Zhu, Christopher B. Johnson, Ana C. Edwards, Lin Kong, Emily K. Jeng, Kaiping Han, Warren D. Marcus, Mark P. Rubinstein, Peter R. Rhode, and Hing C. Wong

Oncogenic NRAS, Required for Pathogenesis of Embryonic Rhabdomyosarcoma, Relies upon the HMGAA2–IGF2BP2 Pathway
Zhizhong Li, Yunyu Zhang, Krishnan Ramanujan, Yan Ma, David G. Kirsch, and David J. Glass

Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity
Xin He, Nicholas Arrotta, Deepa Radhakrishnan, Yu Wang, Todd Romigh, and Charis Eng

Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner
Thomas A. Mace, Zeenath Ameen, Amy Collins, Sylwia Wojcik, Markus Maier, Gregory S. Young, James R. Fuchs, Tim D. Eubank, Wendy L. Frankel, Tanios Bekaii-Saab, Mark Bloomston, and Gregory B. Lesinski

Inhibition of Histone Demethylase JMJD1A Improves Anti-Angiogenic Therapy and Reduces Tumor-Associated Macrophages
Tsuyoshi Osawa, Rika Tsuchida, Massashi Muramatsu, Tepppei Shimamura, Feng Wang, Jun-ichi Suehiro, Yasuharu Kanki, Youichiro Wada, Yuhihiyo Yuyasa, Hiroyuki Ichihara, Hiroaki Asano, Kazunori Tsukuda, Nagio Takigawa, Katsuya Kiura, Adi F. Gazdar, Wan L. Lam, and Shinichiro Miyoshi

Precis: Studies identify mechanisms behind the poor survival of obese leukemia patients through impaired asparaginase response.

Precis: A well-known stromal cell population found in pancreatic tumors is found to secrete soluble factors that convert myeloid cells to an immunosuppressive phenotype that promotes tumoral immune escape and progression.

Precis: Findings highlight a strategy to target cancer cells resistant to hypoxia and nutrient starvation as an approach to heighten sensitivity to antiangiogenic drugs and to reduce risks of drug resistance and tumor recurrence.

Precis: Findings suggest that HSP90 inhibitors being evaluated in clinical trials may be efficacious against deadly brain tumors that express a particular type of cancer stem-like cell.

Precis: Findings identify the upstream elements controlling a core oncogenic driver in embryonic rhabdomyosarcomas, suggesting novel points to target therapeutic inventions against this aggressive pediatric tumor.

Precis: In lung cancer, malignant cells with stem cell-like properties appeared as acquired resistance emerged to EGFR inhibitors, reinforcing concerns that while such treatments may be effective initially, they may also promote progression at later times.

Precis: The results of this study may help resolve the loose genotype-phenotype correlations that occur in a spectrum of clinical syndromes, marked by germline PTEN mutations, by tracing their common effects to alterations in proteasome activity that are affected both by PTEN protein stability and subcellular localization.
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Ryohei Katayama, Aki Aoyama, Takao Yamori, Jie Qi, Tomoko Oh-hara, Youngchul Song, Jeffrey A. Engelman, and Naoya Fujita

Precis: This study finds that a drug in clinical trials exerts its antitumor activity by blocking tubulin polymerization as well as c-Met activity.

3097

RXRα Inhibits the NRF2-ARE Signaling Pathway through a Direct Interaction with the Neh7 Domain of NRF2
Hongyan Wang, Kaihua Liu, Miao Geng, Peng Gao, Xiaoyuan Wu, Yan Hai, Yangxia Li, Yulong Li, Lin Luo, John D. Hayes, Xi Jun Wang, and Xiwen Tang

Precis: This seminal report advances knowledge about how the cytoprotective transcription factor Nrf2 mediates drug resistance in many cancers and how these effects can be overcome to improve outcomes.

3109

Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer
Masaki Shiotai, Jennifer L. Bishop, Ka Mun Nip, Anousheh Zardan, Ario Takeuchi, Thomas Cordonnier, Eliana Beraldi, Jenny Bazov, Ladan Fazli, Kim Chi, Martin Gleave, and Amina Zoubidi

Precis: Preclinical and clinical studies demonstrate the efficacy of targeting the chaperone Hsp27 in reducing metastases in prostate cancer, with potentially broader implications in human cancers generally where this molecule may support stem-like functions.

3120

Novel Therapeutic Strategy to Prevent Chemotherapy-Induced Persistent Sensory Neuropathy By TRPA1 Blockade
Gabriela Trevisan, Serena Materazzi, Camilla Fusi, Alessandra Altomare, Giancarlo Aldini, Maura Lodovici, Riccardo Patacchini, Pierangelo Geppetti, and Romina Nassini

Precis: With an increasing number of cancer survivors, it is important for researchers to direct more attention to preventing or ameliorating the side-effects they suffer, such as chemotherapy-induced neuropathies that are as yet little understood or studied.

3132

A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation-Driven Colorectal Tumor Growth
Ted Lau, Emily Chan, Marilena Callow, Jo Waaler, Jason Boggs, Robert A. Blake, Steven Magnuson, Amy Sambrone, Melissa Schutten, Ron Firestein, Ondrej Machon, Vladimir Korinek, Edna Choo, Dolores Diaz, Mark Merchant, Paul Polakis, Daniel D. Holsworth, Stefan Krauss, and Mike Costa

Precis: Results establish preclinical proof-of-concept for the use of tankyrase inhibitors in APC-mutant colorectal cancer, uncovering potential diagnostic and safety concerns to be overcome as clinical evaluation proceeds.

3145

β1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma
W. Shawn Carbonell, Michael Delay, Arman Jahangiri, Catherine C. Park, and Manish K. Aghi

Precis: Enthusiasm about antiangiogenic therapy for glioblastoma has dampened due to lack of sustained responses, resulting from acquired resistance found in this study to be mediated by β1 integrin, a targetable factor mediating interaction between tumor cells and their microenvironment.

3155

Trop-2 Promotes Prostate Cancer Metastasis By Modulating β1 Integrin Functions
Marco Trerotola, Danielle L. Jernigan, Qin Liu, Javed Siddiqui, Alessandro Fatatis, and Lucia R. Languino

Precis: Targeting the transmembrane molecule Trop-2 may provide a route to block metastatic dissemination.

3168

NEDD9 Depletion Destabilizes Aurora A Kinase and Heightens the Efficacy of Aurora A Inhibitors: Implications for Treatment of Metastatic Solid Tumors
Ryan J. Ice, Sarah L. McLaughlin, Ryan H. Livengood, Mark V. Culp, Erik R. Eddy, Alexey V. Ivanov, and Elena N. Pugacheva

Precis: Provocative findings suggest a rationale to use inhibitors of a mitotic regulatory kinase in treatment of metastatic tumors, with predicted sensitivities correlated to tumor expression of the prometastatic regulatory factor NEDD9.
β-Catenin/POU5F1/SOX2 Transcription Factor Complex Mediates IGF-1 Receptor Signaling and Predicts Poor Prognosis in Lung Adenocarcinoma

Chuan Xu, Dan Xie, Shi-Cang Yu, Xiao-Jun Yang, Li-Ru He, Jing Yang, Yi-Fang Ping, Bin Wang, Lang Yang, Sen-Lin Xu, Wei Cui, Qing-Liang Wang, Wen-Juan Fu, Qing Liu, Cheng Qian, You-Hong Cui, Jeremy N. Rich, Hsiang-Fu Kung, Xia Zhang, and Xiu-Wu Bian

Précis: This potentially seminal study reports a novel complex that mediates self-renewal of cancer stem-like cells in lung cancers and perhaps other epithelial tumors.

ABOUT THE COVER

Rapid acquired resistance to antiangiogenic therapies such as bevacizumab limits clinical utility of this approach in highly vascular tumors including glioblastoma multiforme. β1 integrins represent a critical pathway for the promotion of malignant progression and acquired therapy resistance in cancer cells through adhesive interactions with the surrounding tumor microenvironment. Using a multimodal approach, it was found that the β1 integrin subunit was functionally upregulated in patient glioblastoma specimens with acquired resistance to bevacizumab. Knockdown or inhibition of the β1 integrin subunit with neutralizing monoclonal antibodies promoted reversion of malignant phenotype and attenuated in vivo growth of bevacizumab-resistant glioblastoma xenografts. For details, see article by Carbonell and colleagues on page 3145.